Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACTU Actuate Therapeutics	$5.70 -1.1%	$8.21	$5.50 ▼ $11.99	$111.05M	N/A	60,797 shs	27,260 shs
MCRB Seres Therapeutics	$13.97 -0.7%	$9.14	$6.53 ▼ $29.40	$121.39M	2.75	128,793 shs	23,184 shs
RNTX Rein Therapeutics	$1.40 -1.4%	$1.76	$1.33 ▼ $4.40	$31.01M	1.22	47,713 shs	12,496 shs
TARA Protara Therapeutics	$3.20 +3.9%	$3.12	$1.60 ▼ $10.48	$123.03M	1.35	797,955 shs	75,964 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACTU Actuate Therapeutics	0.00%	-6.19%	-22.89%	-31.18%	+575,999,900.00%
MCRB Seres Therapeutics	0.00%	+11.93%	+90.14%	+88.05%	-42.57%
RNTX Rein Therapeutics	0.00%	-1.39%	-7.79%	-20.22%	+141,999,900.00%
TARA Protara Therapeutics	0.00%	+0.98%	+0.98%	-20.00%	+38.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACTU Actuate Therapeutics	2.0638 of 5 stars	3.5	0.0	0.0	0.0	1.1	3.3	0.0
MCRB Seres Therapeutics	2.8815 of 5 stars	2.9	1.0	0.0	4.6	1.1	0.8	0.0
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	1.5731 of 5 stars	3.6	1.0	0.0	0.0	1.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACTU Actuate Therapeutics	3.00	Buy	$20.50	259.96% Upside
MCRB Seres Therapeutics	1.75	Reduce	$73.67	427.51% Upside
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A
TARA Protara Therapeutics	3.14	Buy	$20.50	540.83% Upside

Current Analyst Ratings Breakdown

Latest RNTX, MCRB, ACTU, and TARA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00
5/22/2025	TARA Protara Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$21.00
5/8/2025	MCRB Seres Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$1.25 ➝ $6.00
4/28/2025	TARA Protara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00 ➝ $23.00
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
MCRB Seres Therapeutics	$126.32M	0.97	N/A	N/A	$1.61 per share	8.67
RNTX Rein Therapeutics	N/A	N/A	$0.44 per share	3.17	$0.43 per share	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	$4.77 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	N/A	-339.73%	N/A
MCRB Seres Therapeutics	$140K	-$4.60	N/A	N/A	N/A	N/A	-41,084.76%	-55.87%	8/12/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A
TARA Protara Therapeutics	-$44.60M	-$1.72	N/A	N/A	N/A	N/A	-36.37%	-33.29%	8/5/2025 (Estimated)

Latest RNTX, MCRB, ACTU, and TARA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	MCRB Seres Therapeutics	-$2.72	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	TARA Protara Therapeutics	-$0.43	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	ACTU Actuate Therapeutics	-$0.26	-$0.32	-$0.06	-$0.32	N/A	N/A
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/8/2025	Q1 2025	TARA Protara Therapeutics	-$0.47	-$0.29	+$0.18	-$0.29	N/A	N/A
5/7/2025	Q1 2025	MCRB Seres Therapeutics	-$0.67	-$2.24	-$1.57	$3.75	$10.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
MCRB Seres Therapeutics	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TARA Protara Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACTU Actuate Therapeutics	N/A	0.46	0.46
MCRB Seres Therapeutics	N/A	2.11	2.11
RNTX Rein Therapeutics	N/A	1.39	1.39
TARA Protara Therapeutics	N/A	18.03	18.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACTU Actuate Therapeutics	N/A
MCRB Seres Therapeutics	59.34%
RNTX Rein Therapeutics	90.89%
TARA Protara Therapeutics	38.13%

Insider Ownership

Company	Insider Ownership
ACTU Actuate Therapeutics	69.34%
MCRB Seres Therapeutics	4.70%
RNTX Rein Therapeutics	5.10%
TARA Protara Therapeutics	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACTU Actuate Therapeutics	10	19.62 million	6.02 million	N/A
MCRB Seres Therapeutics	330	8.73 million	8.32 million	Optionable
RNTX Rein Therapeutics	9	22.15 million	21.02 million	N/A
TARA Protara Therapeutics	30	38.58 million	33.76 million	Optionable

RNTX, MCRB, ACTU, and TARA Headlines

Recent News About These Companies

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - The Manila Times

July 2, 2025 | manilatimes.netM

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 2, 2025 | morningstar.comM

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community - Nasdaq

July 2, 2025 | nasdaq.com

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

Protara Therapeutics, Inc. Added to Russell 3000® Index, Enhancing Visibility in Financial Community

June 30, 2025 | quiverquant.comQ

Protara Therapeutics Announces Addition to the Russell 3000® Index

June 30, 2025 | globenewswire.com

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Buy" by Brokerages

June 30, 2025 | marketbeat.com

Protara Therapeutics, Inc. (TARA) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors

June 23, 2025 | quiverquant.comQ

Protara Therapeutics: Marching On To A Hopefully Eventful Back Half Of 2025

June 14, 2025 | seekingalpha.com

Chutes & Ladders—Protara gears up for next steps with commercial pro

June 7, 2025 | fiercebiotech.comF

The Escalator: Digitas Health, Bristol Myers Squibb, Inizio Evoke and more

June 4, 2025 | mmm-online.comM

Protara Therapeutics names new Chief Commercial Officer

June 4, 2025 | investing.com

Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer

June 2, 2025 | globenewswire.com

Jones Trading Initiates Coverage of Protara Therapeutics (TARA) with Buy Recommendation

May 23, 2025 | msn.com

Richard Levy Spends US$64k On Protara Therapeutics Stock

May 22, 2025 | finance.yahoo.com

With 73% ownership, Protara Therapeutics, Inc. (NASDAQ:TARA) boasts of strong institutional backing

May 16, 2025 | finance.yahoo.com

Protara Therapeutics to Participate in Upcoming Investor Conferences

May 13, 2025 | globenewswire.com

Protara Therapeutics Reports Q1 2025 Financial Results

May 10, 2025 | tipranks.com

Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

How Protara Therapeutics Reflects Shifts Among Nasdaq Companies by Market Cap

May 3, 2025 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Stocks Poised to Benefit From the "Big Beautiful Bill"
By Nathan Reiff | July 7, 2025
View 3 Stocks Poised to Benefit From the "Big Beautiful Bill"
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
3 ETFs to Buy as the One Big Beautiful Bill Rolls Out
By Nathan Reiff | July 21, 2025
View 3 ETFs to Buy as the One Big Beautiful Bill Rolls Out
5 Robotics Stocks to Buy for the Future of Automation
By Ryan Hasson | July 14, 2025
View 5 Robotics Stocks to Buy for the Future of Automation
Taiwan Semiconductor May Profit from Chinese Manufacturing Issues
By Gabriel Osorio-Mazilli | July 8, 2025
View Taiwan Semiconductor May Profit from Chinese Manufacturing Issues

RNTX, MCRB, ACTU, and TARA Company Descriptions

Actuate Therapeutics NASDAQ:ACTU

$5.70 -0.07 (-1.13%)

As of 12:39 PM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Seres Therapeutics NASDAQ:MCRB

$13.96 -0.11 (-0.75%)

As of 12:39 PM Eastern

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Rein Therapeutics NASDAQ:RNTX

$1.40 -0.02 (-1.42%)

As of 11:44 AM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Protara Therapeutics NASDAQ:TARA

$3.20 +0.12 (+3.86%)

As of 12:38 PM Eastern

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time